Interim report January - March 2022
Gothenburg, May 5, 2022 - Vicore Pharma Holding AB (publ) publishes the interim report for the first quarter 2022.Important events during the first quarter · In February, an interim analysis of the AIR phase 2 trial in idiopathic pulmonary fibrosis (IPF) suggested that C21 stabilizes disease and shows an unanticipated increase in lung function in IPF patients. · In February, Vicore announced the advancement of its first new chemical entity (C106) from the VP03 program to a first in human phase 1 trial. · In March, Vicore announced the plan to initiate a proof-of-concept trial